• United Therapeutics Chairperson and CEO Martine A. Rothblatt reported sales totaling 9,500 common shares on June 8, 2026.
• Shares sold at weighted-average prices ranging from $544.89 to $551.37.
• Directly owned common shares fell to 40,513 following the transactions.
• Rothblatt also exercised stock options for 9,500 shares at $146.03 on the same day.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000072), on June 09, 2026, and is solely responsible for the information contained therein.